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an overwhelming consensus that low doses have largely eliminated 
pulmonary toxicity as a reason to withdraw amiodarone therapy in 
the first place. As Magro et al. (2) put it, “ to withhold or 
withdraw potentially lifesaving therapy from patients frequently 
resistant to all other available antiarrhythmic medications based on 
preexisting abnormalities or a reduction in pulmonary function alone 
does not appear to be justified in the case of amiodarone.” 
In the use of amiodarone one has to remember that “poison is in 
everything, and no thing is without a poison. The dosage makes it 
either a poison or a remedy” (23). 
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Reply 
I agree with Kerin and Rubenfire that the incidence of pulmonary 
toxicity caused by amiodarone is reduced when the loading and 
maintenance doses of amiodarone are lowered. I appreciate their 
agreement that routine serial pulmonary function studies are not 
indicated in the follow-up of patients receiving amiodarone therapy. 
LEONARD N. HOROWITZ. MD. FACC 
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Dilated Cardiomyopathy 
Dystrophy 
in Myotonic 
Nguyen et al. (1) noted that 6 of their 12 autopsy cases of myotonic 
dystrophy had cardiac enlargement that was consistent with dilated 
cardiomyopathy in 3 cases. They cite other authors who have 
observed clinically undiagnosed cardiomegaly in autopsy cases. 
Perloff et al. (2) did not find echocardiographic evidence of ventric- 
ular dysfunction in their patients. We report a patient with the 
uncommon association of myotonic dystrophy and dilated cardio- 
myopathy with clinically overt congestive heart failure in the 
absence of an underlying chronic rhythm disturbance. 
A 42 year old white man with a history of progressive “hand 
stiffness” since adolescence presented to his family doctor with a 2 
year history of increasing shortness of breath and was found to be in 
congestive heart failure. He was transferred to our center for cardiac 
evaluation. On physical examination there was a paucity of cardio- 
vascular findings. The heart tones were distant; there was no atria1 
or ventricular gallop, murmur or increased jugular venous pressure. 
Chest radiographs showed massive cardiomegaly and mild pulmo- 
nary vascular congestion. The electrocardiogram showed normal 
sinus rhythm with left bundle branch block and a slightly prolonged 
PR interval (0.21 s). 
M-mode and two-dimensional echocardiography demonstrated a 
dilated, poorly contracting left ventricle with markedly diminished 
left ventricular ejection fraction (~10%). At cardiac catheterization, 
the right heart pressures were normal (right ventricle 20112 and 
pulmonary artery 2011.5 mm Hg, mean 18). The pulmonary capillary 
wedge pressure was 14 mm Hg and left ventricular pressure 90115 
mm Hg. There was mild systemic hypotension (aorta 90170 mm Hg). 
Thermodilution cardiac output was markedly diminished (1.32 liters/ 
min). Pulmonary vascular resistance was not elevated, but systemic 
vascular resistance was elevated (4.12 dynes/slcmm5). Left ventric- 
